Tresiba Overdose and Accidental Excess Dose: Recognition, Treatment, and Prevention

Why Tresiba Overdoses Last Longer Than Other Insulin Overdoses

Insulin degludec forms multi-hexamer chains after subcutaneous injection, creating a soluble depot that releases monomers slowly over more than 42 hours. This pharmacokinetic profile, which makes Tresiba effective as a once-daily basal insulin, becomes a clinical liability during overdose. The half-life of approximately 25 hours means that excess insulin continues absorbing from the injection site long after the event 1.

The Multi-Hexamer Depot Effect

When Tresiba is injected, zinc and phenol in the formulation support the formation of long chains of insulin hexamers. These chains slowly dissociate into di-hexamers and then monomers that enter the bloodstream. In a standard dose, this mechanism produces a flat, peakless insulin profile over 24 hours. In an overdose, the depot is simply larger. More hexamer chains form, more monomers are released per hour, and the glucose-lowering effect intensifies and extends 2.

Comparison to Shorter-Acting Basal Insulins

Insulin glargine (Lantus) has a half-life of roughly 12 hours. NPH insulin peaks at 4 to 8 hours and is largely cleared by 16 hours. An overdose of either produces a hypoglycemic window that clinicians can bracket with reasonable confidence. Tresiba overdoses are different. Blood glucose may rebound temporarily with treatment, then drop again 6, 12, or even 18 hours later as the depot continues releasing insulin. This recurrent hypoglycemia pattern is the primary reason Tresiba overdoses require extended monitoring 3.

Recognizing an Insulin Degludec Overdose

Symptoms of insulin overdose are symptoms of hypoglycemia, and they progress through predictable stages. The challenge with Tresiba is that symptom onset may be delayed relative to shorter-acting insulins, and patients sometimes feel fine for 1 to 2 hours before developing neuroglycopenic signs.

Mild to Moderate Hypoglycemia (Blood Glucose 54 to 70 mg/dL)

Adrenergic symptoms appear first: tremor, sweating, palpitations, anxiety, and hunger. These are the body's counter-regulatory response to falling glucose. Patients remain fully conscious and can self-treat. A blood glucose reading confirms the clinical picture.

Severe Hypoglycemia (Blood Glucose <54 mg/dL)

Neuroglycopenic symptoms dominate: confusion, slurred speech, visual disturbances, seizures, and loss of consciousness. The American Diabetes Association defines severe hypoglycemia as any event requiring assistance from another person, regardless of the measured glucose value 4. Severe events from Tresiba overdose carry the added risk of recurring after initial correction.

Delayed Presentation

Because insulin degludec has no pronounced peak, some overdose patients present to emergency departments hours after injection with gradually worsening symptoms rather than an acute crisis. A patient who accidentally took 100 units instead of 10 units may not develop significant hypoglycemia for 2 to 3 hours if they ate a large meal around the time of injection. This delay can create a false sense of reassurance.

Immediate Management: What to Do After an Excess Dose

Treatment depends on whether the patient is at home or in a clinical setting, and on symptom severity. The priority in every case is the same: restore and maintain blood glucose above 70 mg/dL.

At-Home Response for Conscious Patients

A patient who realizes they injected too much Tresiba should immediately consume 15 to 20 g of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon of sugar dissolved in water). They should recheck blood glucose in 15 minutes and repeat the carbohydrate if glucose remains below 70 mg/dL. This is the standard "Rule of 15" endorsed by the ADA 5.

The critical difference with Tresiba: the Rule of 15 may need to be repeated many times over 24+ hours. Patients should not assume the crisis has passed after a single correction.

When to Call Emergency Services

Any of these findings should trigger a call to 911 or the local emergency number:

• Loss of consciousness or seizure
• Blood glucose below 54 mg/dL that does not respond to two rounds of oral glucose
• Dose exceeding twice the prescribed amount
• Patient lives alone and cannot guarantee continuous self-monitoring for 24 hours
• Intentional overdose, regardless of symptoms

Glucagon Administration

If the patient is unconscious or unable to swallow, a bystander should administer glucagon. Nasal glucagon (Baqsimi, 3 mg) or injectable glucagon (1 mg IM) will temporarily raise blood glucose by mobilizing hepatic glycogen stores. The effect typically lasts 60 to 90 minutes. Because Tresiba's glucose-lowering action outlasts glucagon's effect by many hours, glucagon is a bridge to emergency medical care, not definitive treatment 6.

Emergency Department and Inpatient Management

IV Dextrose Protocol

For severe or refractory hypoglycemia, emergency physicians administer 25 g of dextrose as a 50 mL bolus of D50W (50% dextrose in water). This raises blood glucose by approximately 100 mg/dL within minutes. Given the prolonged action of degludec, a continuous infusion of D10W (10% dextrose) is typically started immediately after the bolus, titrated to maintain glucose between 100 and 180 mg/dL 7.

Extended Monitoring Requirements

The FDA-approved labeling for insulin degludec notes a duration of action exceeding 42 hours at therapeutic doses 8. In overdose, the duration may extend further. Published case reports of ultra-long-acting insulin overdose describe recurrent hypoglycemia episodes up to 48 hours post-ingestion.

A reasonable monitoring schedule includes:

• Blood glucose every 15 to 30 minutes during the first 2 hours of IV dextrose
• Every 1 hour for hours 2 to 12
• Every 2 hours for hours 12 to 24
• Every 4 hours for hours 24 to 48, if the patient required significant dextrose support

ICU vs. Floor Admission

Patients who require continuous dextrose infusion or who presented with seizure or loss of consciousness should be admitted to an ICU or step-down unit with continuous glucose monitoring capability. Those with mild overdoses (1.5x the prescribed dose, no neuroglycopenic symptoms, glucose maintained above 70 mg/dL with oral intake) may be observed in the emergency department for 12 to 24 hours with serial glucose checks before discharge.

The DEVOTE Trial: Hypoglycemia Risk at Standard Doses

The DEVOTE trial (N=7,637) randomized patients with type 2 diabetes to insulin degludec vs. Insulin glargine U100, with a primary endpoint of major adverse cardiovascular events. Degludec was non-inferior to glargine for MACE (HR 0.91, 95% CI 0.78 to 1.06). The secondary safety finding was more clinically striking: degludec reduced severe hypoglycemia by 40% (rate ratio 0.60, 95% CI 0.44 to 0.82) and severe nocturnal hypoglycemia by 53% (rate ratio 0.47, 95% CI 0.31 to 0.73) compared to glargine 9.

What DEVOTE Means for Overdose Context

This lower baseline hypoglycemia risk at therapeutic doses does not make Tresiba overdoses safer. It does mean that patients who are properly dosed on degludec are less likely to experience the day-to-day dose stacking that sometimes leads to accidental overdose with twice-daily insulin regimens. The flat pharmacokinetic profile is protective at the right dose and dangerous at the wrong one.

How Tresiba Works: Mechanism Relevant to Overdose Pharmacology

Understanding degludec's mechanism clarifies why overdose management requires patience.

Molecular Structure

Insulin degludec is a modified human insulin with a 16-carbon fatty diacid chain attached to lysine at position B29 via a glutamic acid spacer. This acylation allows the molecule to bind albumin in the bloodstream, which further slows clearance and extends duration of action. The combination of subcutaneous depot formation and albumin binding produces a terminal half-life of approximately 25 hours, roughly twice that of insulin glargine 1.

Receptor Binding and Glucose Uptake

Like all insulins, degludec binds the insulin receptor on muscle, adipose, and hepatic cells. It suppresses hepatic glucose output and promotes glucose uptake into peripheral tissues. In overdose, this suppression is excessive: the liver cannot release enough glucose to compensate, and peripheral tissues continue pulling glucose from the bloodstream faster than the body can replenish it 10.

Why You Cannot "Remove" the Depot

Unlike an oral drug overdose treatable with activated charcoal, or a drug with a specific reversal agent (like naloxone for opioids), insulin degludec has no antidote. The subcutaneous depot cannot be surgically excised in a meaningful way because the multi-hexamer chains disperse through the tissue rapidly. Hemodialysis does not remove insulin effectively. Management is entirely supportive: replace glucose faster than insulin can clear it until the drug is eliminated 7.

Special Populations and Overdose Risk

Elderly Patients

Older adults with reduced renal function clear insulin more slowly. The FDA label notes that insulin degludec pharmacokinetics are not significantly altered in mild-to-moderate renal impairment, but severe renal impairment (eGFR <30 mL/min) may prolong the effect. Elderly patients also have blunted counter-regulatory hormone responses, meaning they may not develop the adrenergic warning symptoms (tremor, sweating) that prompt younger patients to eat. This "hypoglycemia unawareness" increases the risk of progressing directly to neuroglycopenia 4.

Patients on Sulfonylureas or Other Insulin

Patients taking sulfonylureas (glipizide, glyburide) alongside Tresiba face compounded hypoglycemia risk during an overdose event. The sulfonylurea stimulates endogenous insulin secretion on top of the exogenous excess. Clinicians managing such patients should consider the total insulin burden and may need higher dextrose infusion rates.

Type 1 vs. Type 2 Diabetes

Patients with type 1 diabetes have no endogenous insulin production and therefore no ability to "turn off" insulin secretion as a counter-regulatory measure. Their glycogen stores may also be less reliable. A type 1 patient who overdoses on Tresiba may experience more severe and more prolonged hypoglycemia than a type 2 patient who overdosed on the same relative excess.

Preventing Accidental Tresiba Overdoses

Dose Verification Habits

The most common accidental overdose scenario is a tenfold error: a patient prescribed 10 units dials the pen to 100 units, or a patient prescribed 30 units injects 300 units from a U-200 pen without realizing the concentration. Tresiba is available in U-100 (100 units/mL) and U-200 (200 units/mL) formulations. The U-200 FlexTouch pen dials in the same unit increments as U-100 (the pen mechanism accounts for the concentration difference), but confusion can arise when patients switch between devices 8.

Pen Sharing Prohibition

Tresiba pens must never be shared between patients, even with a new needle. Cross-contamination risk aside, using another person's pen with an unfamiliar dose setting is a direct pathway to overdose.

Timing Flexibility and Dose Stacking

Tresiba's labeling permits flexible once-daily dosing with a minimum of 8 hours between doses. This flexibility reduces the risk of dose stacking that occurs when patients forget whether they took their injection and take a second one. Patients should record each injection in a log or use a pen with a dose memory function 9.

Prescriber Communication

Prescribers should explicitly discuss overdose scenarios during initial Tresiba education. Patients should know: if you accidentally inject more than prescribed, eat immediately, check your blood sugar every 30 minutes, and call your provider or go to the emergency department if glucose drops below 70 mg/dL despite eating.

Post-Overdose Follow-Up

After discharge from hospital observation, patients should continue monitoring blood glucose every 4 to 6 hours for an additional 24 hours. Their prescriber should review the event to identify the root cause (pen confusion, vision impairment, cognitive factors, or intentional self-harm). Dose adjustments may be warranted. If the overdose was intentional, psychiatric follow-up and a safety plan must be in place before the patient resumes self-administered insulin.

The Endocrine Society recommends structured insulin self-management education after any hypoglycemic event requiring emergency intervention, with documented reassessment at 2 and 4 weeks 11.

Patients discharged after a Tresiba overdose should have glucagon prescribed (nasal or injectable) and a household member trained in its administration before leaving the hospital.